By Mill Chart
Last update: Apr 5, 2025
Consider EXELIXIS INC (NASDAQ:EXEL) as an affordable growth stock, identified by our stock screening tool. EXEL is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of EXEL, the assigned 8 reflects its growth potential:
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. EXEL has earned a 7 for valuation:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of EXEL, the assigned 9 reflects its health status:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. EXEL scores a 8 out of 10:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of EXEL
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
41.59
-0.19 (-0.45%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.